Objective:

To discuss the emergence and challenges of nitrosamine testing in pharmaceuticals, particularly following the detection of NDMA in valsartan, which triggered a global investigation.

Approach:

• Historical Context: The article discusses the initial awareness of nitrosamines among professionals in the pharmaceutical industry, particularly following the discovery of NDMA in valsartan.
• Analytical Method Development: Various professionals describe their experiences in developing analytical methods for detecting nitrosamines, including LC-MS techniques.
• Regulatory Response: The article highlights the regulatory actions taken by the EMA and FDA in response to nitrosamine contamination in pharmaceuticals.

Key Findings:

• Nitrosamines, including NDMA, are classified as probable human carcinogens.
• Different nitrosamines have varying acceptable intake levels based on their carcinogenic potency, ranging from 26.5 ng/day for high potency to 1500 ng/day for lower potency.
• Nitrosamines can form during pharmaceutical manufacturing processes and from interactions between APIs and excipients.

Interpretation:

Nitrosamines pose significant analytical challenges due to their low permissible levels and potential health risks, necessitating sensitive detection methods.

Limitations:

• The article does not provide specific data on the prevalence of nitrosamines in pharmaceuticals, which is a significant gap.
• It lacks detailed information on the effectiveness of current testing methodologies.

Conclusion:

The detection and analysis of nitrosamines in pharmaceuticals remain critical due to their potential health risks and the regulatory scrutiny they attract.